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Microﬂuidic synthesis of PLGA/carbon quantum
dot microspheres for vascular endothelial growth
factor delivery
Meisam Omidi,

a

Mohadeseh Hashemibc and Lobat Tayebi

*a

In this study, vascular endothelial growth factor (VEGF) loaded poly(D,L-lactide-co-glycolide) (PLGA) –
carbon quantum dot microspheres were produced using microﬂuidic platforms. The microcapsules were
fabricated in ﬂow-focusing geometry with a biphasic ﬂow to generate solid/oil/water (s–o–w) droplets.
To avoid any damage to protein functional and structural stability during the encapsulation process, the
VEGF was PEGylated. The produced microspheres were intact and highly monodisperse in size (CV <
5%). Furthermore, microspheres in a size range of 16–36 mm were achieved by adjusting the ﬂow ratio
parameter. The encapsulation eﬃciency, release proﬁle, and bioactivity of the produced microparticles
were also studied. The loading eﬃciency of PEGylated VEGF in the microparticles was varied from 51–
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69% and more than 90% of PEGylated VEGF was released within 28 days. Furthermore, the release of
VEGF was indirectly monitored by carbon quantum dots. The present monodisperse and controllable

DOI: 10.1039/c9ra06279c

VEGF loaded microspheres with reproducible manner could be widely used in tissue engineering and

rsc.li/rsc-advances

therapeutic applications.

1. Introduction
Vascularization is a complex and multi-step physiological
process that plays an essential role in tissue engineering.1 There
are various clinical problems associated with poor vascularity in
craniomaxillofacial tissue repair and regeneration. Some
examples include treatment of critically sized oral and craniomaxillofacial defects in which the size of the defect hinders
vascularity of a non-vascularized bone gra,2–4 or even small
defects that have to be treated in particular conditions, such as
aer radiation therapy which creates poor vascularity.4–8 Moreover, some methods to seed stem cells into the gra materials
have been reported, but in these techniques, the cell viability in
the deep portion of large scaﬀolds is compromised as a result of
poor vascularization and following hypoxia and inadequate
nutrient transport.9–11 In general, problems in functional
vascularization lead to a lack of gra integration and the ultimate failure of craniomaxillofacial tissue-engineered products.
Delivery of VEGF is highly challenging as its bolus injection,
or the long/excessive amounts of exposure can cause improper
neovascularization and carry the risk of tumorigenesis.12 On the
other hand, and due to its short half-life, slow and short-lived
exposure to VEGF produces transient and oen short-lived
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neoangiogenesis. Thus, both localized and controlled sustained release of VEGF is extremely important. Administration
of polydisperse VEGF-loaded particles into the body, and in
turn, having diﬀerent release rates in diﬀerent local areas of the
target tissue is not safe in VEGF delivery. There are diﬀerent
types of carriers that have been designed and oﬀered for growth
factor deliveries, but a vigorous predictive technique for the
production of these carriers is yet to be accomplished.14–20 Poly(D,L-lactide-co-glycolide), (PLGA) is known as an attractive
delivery vehicle due to its excellent biocompatibility, high safety
prole, and FDA approval for use in drug.21 The biomolecules
can be sustainably released by hydrolytically degradation of
PLGA over time in vivo or in vitro.22 Besides, the release kinetics
of this system can be easily adjusted by altering the molecular
weight and lactide/glycolide ratio. Thus PLGA can be known as
an appropriate candidate for control delivery of VEGF.
The microuidic method is known as the appropriate
approach for the production of microparticles with precise
control over the characteristics. Although the on-chip approach
was successfully applied for encapsulating small molecule
drugs,23–26 using this technique for loading proteins is remains
a challenging issue.26,27 Generally, proteins such as growth
factor have sensitive structures, and their functionality can be
aﬀected by chemical degradation and physical denaturation
during the encapsulation process.28 To overcome these issues,
several approaches such as ion-pairing proteins, using human
serum albumin or surfactants, and protein PEGylation have
been proposed by literature in recent years.29–31 Despite these
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mammalian cells and F-12K cell culture media were purchased
from Thermo Fisher (USA).

extensive eﬀorts, fabrication of protein-loaded particle still
known as a daunting task.
Carbon quantum dots (CQDs) are the new carbon derivative
nanomaterials with the tiny size of 2–10 nm. At such a size scale,
CQDs experience the domination of quantum connement eﬀect,
which leads to the formation of electron–hole pairs with the
dimensions smaller than the exciton Bohr radius.32–34 CQDs with
outstanding features such as excellent optical properties, biocompatibility, and facile surface modication, have drawn attention.35
In this study, solid/oil/water (s–o–w), microuidic platform was
developed for encapsulation of PEGylated VEGF in PLGA – CQDs
microspheres. Finely tune the microparticles' characteristics such
as size, microstructure, loading eﬃciency, and release proles can
be achieved by using the present microuidic approach. The
fabrication process, characterization, release prole, and bioactivity of the VEGF-loaded microparticles was described.

Poly(ethylene glycol) (PEG) was covalently conjugated to the
VEGF through amine–hydroxysuccinimide (NHS) reaction
(Fig. 1A).36 The typical procedure was as follows, 0.1 mg of VEGF
was dissolved in 0.5 mL of PBS (0.1 M, pH 7.2, 4  C). Also, 6 mg
of acid-PEG9-NHS ester was dissolved 1 mL of DMSO. Subsequently, the acid-PEG9-NHS ester solution was added to the
protein solution, in a 150 : 1 molar ratio. This solution was
incubated for two hours at 4  C; then, the unreacted acid-PEG9NHS ester was removed from the obtained solution by using
a dialysis bag (12 000 Da). Finally, PEGylated VEGF was lyophilized and stored at 20  C.

2.

2.3. Characterization of PEGylated VEGF

Material and methods

2.1. Materials
Poly(D,L-lactide-co-glycolide), PLGA (75 : 25, Mw 76 000–
115 000, viscosity of 0.7 dL g1), Mg(OH)2, ammonium hydrogensulfate, dichloromethane (DCM), human VEGF ELISA assay
kit, endothelial cell growth supplement (ECGS), and cell
proliferation reagent WST kit were obtained from Sigma-Aldrich
(USA). Vascular endothelial growth factor-A(165) (VEGF) was
obtained from Cell Applications (USA). Polyvinyl alcohol, (Mw
500–5000) was purchased from VWR (USA), and acid-PEG9-NHS
ester (Mw 5000) was obtained from BroadPharm (USA). West
pico plus chemiluminescent substrate, live/dead kit for

Fig. 1

2.2. PEGylation of VEGF

Western blot assay, Size-exclusion HPLC (SE-HPLC) and MALDITOF mass spectroscopy were used for characterization of
PEGylated VEGF. PEGylation of VEGF was examined by using
Western blot assay. Briey anti-VEGF rabbit polyclonal antibody
(1 : 500 dilution), and goat anti-rabbit antibody conjugated to
horseradish peroxidase (HRP) (1 : 5000 dilution) were used as
primary and secondary antibody respectively. Also, west pico
chemiluminescent substrate was applied for signal generation.
SE-HPLC was performed to identify the diﬀerent fraction of
PEGylated VEGF using BIOshell A400 Protein C4, 2.1 mm 
15 cm column. The diluted sample in PBS buﬀer (1X, pH 7.4)

(A) Illustration of VEGF PEGylation. (B) X-junction microﬂuidic chip designed, and (C) microﬂuidic set up for VEGF-loaded MPs production.

This journal is © The Royal Society of Chemistry 2019
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was injected to the column with a ow rate of 0.5 mL min1;
280 nm UV detector was used to monitor the elution peaks.
MALDI-TOF mass spectroscopy was performed in linear
acquisition operation mode using MALDI TOF Mass Spectrometer (Shimadzu-7090). Briey, MALDI-target was coated
with a saturated solution of sinapinic acid in ethanol. Subsequently, the puried sample (10 mL) was mixed with 10 mL of
sinapinic acid (1% in 40% acetonitrile), and 1 mL of the
resulting mixture was loaded onto the target.

2.4. Synthesis of carbon quantum dots
CQDs was synthesized and characterized as same as the
procedure described in our previous report.32 Briey, ammonium hydrogen citrate (1 g) was added to 30 mL of DI water
under vigorous stirring for 15 minutes. The resulting solution
was transferred to a 100 mL hydrothermal autoclave reactor and
heated up to 180  C for 12 h. Subsequently, the reactor was
cooled down to room temperature. The large particles were
removed from the resulting solution by ltration (0.2 mm) and
sedimentation (10 000 rpm for 20 min). Also, CQDs was puried

Fig. 2
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using dialysis bag (1000 Da). The CQDs were PEGylated by
combining CQDs with acid-PEG9-NHS at a 1 : 150 molar ratio,
at room temperature for 2 h. Aer the reaction was complete,
the unreacted chemical reagent was removed from the obtained
solution by dialysis the components (3400 Da) overnight.

2.5. Fabrication of microuidic platform
A microuidic platform including an X-junction chip (Fig. 1B)
with three inlets and one outlet was used in this study. The chips
were fabricated using conventional photolithographic techniques. Briey, the chips were designed using Solidworks CAD
soware with a channel diameter of 100 mm and then a mask was
made by the optical pattern generator. Photoresist Shipley 1813
was spin-coated on a 50 mm diameter silicon wafer, and the
pattern from the mask was exposed using a contact aligner. The
pattern was etched by inductively coupled plasma ion etcher. So
lithography technique was applied to transfer the mold's patterns
on PDMS and to bind them to the glass slides aer surface
activation using plasma cleaner. The range of ow stability was
regulated by using rhodamine B and uorescein ows.

(A) Western blot assay, (B) analytical HPLC chromatogram, and (C) MALDI-TOF mass spectroscopy of (a): native VEGF (b): PEGylated VEGF.
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2.6. Production of the VEGF-loaded microparticles
VEGF-loaded PLGA microparticles (MPs) were fabricated by the
microuidic droplet approach. In this method, the MPs were
achieved in two steps include in chip droplets formation and
solvent extraction. The droplets uid or solid/oil phase (growth
factor and polymer solution) was prepared as the following
procedure. 100 mg of PLGA (75 : 25, Mw 76 000–115 000) and
5 mg Mg(OH)2 was dissolved in 5 mL dichloromethane (DCM).
Subsequently, 50 mL CQD and 0.1 mg of VEGF was added to
PLGA solution and vortexed for 30 s. The continuous or carrier
uid phase was formed by aqueous surfactant blend (water/
PVA). Briey, 500 mg poly(vinyl alcohol) (PVA) were added to
25 mL water. In order to remove large particles, the solutions
were ltered by 0.2 mm ltrate. The droplets and carrier uid
were transferred under control condition to the microuidic
chip inlet by two syringe pump through FEP tubes (Fig. 1C). The
microuidic chip outlet was collected in a glass beaker containing 100 mL of PBS solution of 2% PVA and continuously
stirred at 200 rpm. The resulting MPs were lyophilized aer
centrifuged and washed with DI water.

2.7. Encapsulation eﬃciency
The amount of proteins encapsulated within PLGA microspheres was measured by full degradation of 5 mg of the
microspheres in 5 mL of 0.1 N NaOH. Aer 24 hours, the

RSC Advances

solution was centrifuged at 5000 rpm for 5 min and the protein
content in the supernatant was measured by ELISA assay kite.
Results were expressed as actual loading and the loading eﬃciency, is dened by the ratio of actual to theoretical loading 
100  standard deviations (S.D.). Standard deviation (S.D.) was
calculated by repeating this test for three diﬀerent samples.
2.8. In vitro release studies
5 mg of VEGF-loaded MPs was dissolved in 1 mL sterile PBS (pH
7.4) and incubated at 37  C. At scheduled time intervals, at
predened time intervals, the samples were centrifuged at
5000 rpm for 5 min and supernatants replaced with the same
volume of fresh PBS. The protein and CQDs content of each
sample were measured by ELISA assay kits and photoluminescence (PL) analysis. The release prole was expressed as
terms of cumulative release from 1 mg of microspheres of three
replicates.
2.9. VEGF bioactivity assay
The proliferative capacity of human umbilical vein endothelial
cell (HUVEC) was used for in vitro bioactivity assay of the VEGF
released from the MPs. HUVEC cell was cultured in 24 well
plates at a density of 4000 cells per well in F-12K medium
supplemented with 1% sodium heparin, 1% penicillin/
streptomycin, 10% fetal bovine serum (FBS) and 20 mg mL1

Fig. 3 (A) Hydrodynamic diameter size distribution of CQDs. The insets: DLS results (B) UV/VIS absorption spectrum of CQDs. The insets: CQDs
image (1 mg mL1) under the sun and UV light (366 nm), and (C) photoluminescence response of CQDs by varying the excitation wavelength
from 246 to 396 nm.

This journal is © The Royal Society of Chemistry 2019
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ECGS. Aer 12 hours cells were treated by VEGF-loaded MPs.
Cell proliferation of each sample was determined aer 5 days
using WST and live/dead assay.32,37

2.10.

Characterization

The size and microstructure of PLGA MPs were investigated 3D
laser measuring microscope (LEXT OLS4000), scanning electron
microscope (SEM) with energy dispersive X-ray detector (EDS)
(JEOL JSM6510LV/LGS) and confocal microscope (Prairie
Technologies, Inc). The PLGA MPs size was determined using
an image analysis method as described previously.13 Five
diﬀerent microscopy images were prepared for each sample,

Paper

and the average diameters and size distributions were determined by ImageJ soware (ImageJ freeware, NIH, USA).
The hydrodynamic diameter size distribution of CQDs sample
was measured by Dynamic Light Scattering (DLS, Malvern ZEN
3600 zetasizer) analysis. 100 mL of CQDs was diluted in 2.5 mL of
PBS buﬀer (1X, pH 7.4), and the diluted sample was transferred to
disposable cuvet for DLS analysis. The measurement was done at
room temperature, and it was repeated ve times.
Ultraviolet-visible (UV/VIS) and photoluminescence (PL)
analysis were carried out by Shimadzu Biospec and Avaspec
2048 TEC respectively. Nikon D5300 was used to taking digital
photos. Cells were visualized under inverted microscopy using
EVOS uorescence microscope (Euroclone, Italy).

(A) Droplet size, and (B) droplet generation rate for diﬀerent values of carrier and droplet ﬂow rate. (C) Droplet size formation in chip at Cd
¼ 6.2 mL min1 with diﬀerent values of carrier ﬂow rate, and (D) droplet generation rate at Cd ¼ 25.2 mL min1 with diﬀerent values of carrier ﬂow
rate. (E) Droplet size variation against carrier ﬂow for two diﬀerent droplet ﬂow includes PLGA\CDs\VEGF and PLGA as control.
Fig. 4
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Results and discussion

Western blot assay, SE-HPLC, and MALDI-TOF mass spectroscopy were performed to conrm the existence of diﬀerent
PEGylated VEGF moiety (Fig. 2). As shown in Fig. 2A(a) two

bands, around 22 kDa appears for native VEGF. These bands are
related to dimer fraction of native VEGF. As expected, the
molecular mass of VEGF notably increased by conjugation of
the acid-PEG9-NHS ester to VEGF (Fig. 2A(b)). HPLC chromatogram of native VEGF shows a single individual peak

Fig. 5 Micrographs and size distribution of VEGF-loaded PLGA MPs (A) Cf ¼ 10 mL min1, Cd ¼ 2.5 mL min1, (B) Cf ¼ 70 mL min1, Cd ¼ 2.5
mL min1, and (C) Cf ¼ 100 mL min1, Cd ¼ 2.5 mL min1, (scale bar ¼ 50 mm). SEM micrograph image of (a) Cf ¼ 10 mL min1, Cd ¼ 2.5 mL min1
(scale bar ¼ 15 mm), EDS elemental mapping of (b) carbon and (c) nitrogen. (D) PLGA MPs, (E) PLGA-CQDs MPs.

This journal is © The Royal Society of Chemistry 2019
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corresponding to free VEGF (Fig. 2B(a)). The chromatogram of
PEGylated VEGF depicts the presence of diﬀerent PEGylated
derivatives of VEGF (I-, II-, and III-peaks) along with a small
amount of unconjugated VEGF (Fig. 2B(b)). MALDI-TOF mass
analyses used to determine the amount of free VEGF in the
sample (Fig. 2C). The MALDI-TOF mass spectrum of PEGylated
VEGF shows that the sample consisted of I-(45%), II-(35%),
III-(15%) and less than 5% of free VEGF. These result indicated that more than 95% VEGF was successful PEGylated.29
Dynamic light scattering (DLS), UV/VIS, and PL spectroscopy
were applied for characterization of the synthesized CQDs
(Fig. 3A–C). According to DLS, results depicted in Fig. 2A, the
average hydrodynamic diameter of CQDs in PBS (pH 7.4) was 4
 1 nm. The UV/VIS and PL spectrum of CQDs presented in
Fig. 2B and C. As shown in Fig. 2B, CQDs had two absorption
peaks at 240 and 350 nm. The absorption peak at 230 nm is
corresponding to p–p* transition of C]O bond and the
absorption peak at 330 is related to the n–p* transition of C]O
bond.32 Photoluminescence spectroscopy analysis was used to
evaluate excitation dependency of CQDs. As presented in
Fig. 2C, the emission wavelength at 460  5 nm was revealed by
CQDs for various excitation wavelengths (220 to 400 nm). The
uniform size distribution and excitation independent behavior
of as-prepared CQDs can be proven by PL characterization.
Herein, the PLGA MPs were achieved in two steps, including
in chip droplets formation and solvent extraction. Generally,
the droplet formation in the microuidic chip depends on
several physical parameters such as viscosities, interfacial
surface tension, and ow ratio (carrier to droplet ow rate). The
eﬀect of carrier (Cf) and droplet ow (Cd) rate on droplet sizes
and generation frequency rate presents in Fig. 4A and B. The
generation frequency rate was dened by the ratio of Cd to the
volume of the droplet. Diﬀerent combination of carrier and
droplet ow rate led to generate at least seven noticeable areas
of droplet size and frequency. The typical droplet size and
frequency related to the selected pointe depict in Fig. 4C and D.
In the constant value of Cd droplet size was decreased, and
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generation frequency rate was increased with Cf increasing
respectively. The eﬀect of diﬀerent droplet ow in droplet size
was also investigated (Fig. 4E) by using PLGA (2% w/v) as
control. The results show that the droplet size aﬀected by
changing droplet ow. Droplet size variation against carrier
ow tow diﬀerent droplet ow includes PLGA\CDs\VEGF and
PLGA as control. The results show that the droplets with a size
range of 30–100 mm and the generation frequency rate range of
1–13 kHz can be produced with this platform.
The PLGA MPs are formed by the residue of polymer and
protein content aer solvent (DCM) extraction from the
synthesis droplet. So, the nal MPs always have a smaller size in
comparison to the initial droplet. The morphology and size
distribution of PLGA MPs were investigated by 3D laser
measuring microscope (Fig. 5A–C). Fig. 5A–C shown that the
PLGA microsphere was intact and highly monodisperse in size
(coeﬃcient of variation <5%). Additionally, PLGA MPs appeared
to have dense and nonporous structure. The burst release of the
drug from the MPs can be inhibited through a non-porous
structure.29 Distribution of CQDs in PLGA MPs was investigated with the SEM and EDS elemental mapping analysis
(Fig. 5D and E). EDS mapping also conrms that CQDs was
uniformly distributed in PLGA MPs.
The variation of the MPs sizes as a function of droplet size
and variation of the droplet size as a function of time for
a tracked droplet is shown in Fig. 6A. Generally, DCM is
removed from the droplet to the carrier/droplet uid interface
through the diﬀusion phenomena immediately aer droplet
formation in a microuidic chip. As shown in Fig. 6A, DCM was
continuously extracted from droplet, and it was fully removed
aer 200 seconds. Based on the initial droplet size, the particle
size of the produced MPs was varied from 16–36 mm. The
current technique for production of microparticles as growth
factor carriers is the bulk mixing method. This approach is
limited as it results in polydisperse particles with numerous
physicochemical characteristics that are diﬃcult to control.
Thus, to have the microparticle of interest, many complicated,

(A) VEGF-loaded PLGA MPs sizes as a function of droplet size. The insets: size reduction proﬁle of a tracked droplet as a function of time
(Cf ¼ 10 mL min1, Cd ¼ 2.5 mL min1). (B) Photoluminescence response of VEGF-loaded PLGA MPs with diﬀerent size (excitation wavelength 400
nm). The insets: ﬂuorescence microscope image of VEGF-loaded PLGA MPs (22 mm) (a): bright ﬁeld and, (b): ﬂuorescence (400 nm), (scale bar ¼
50 mm).
Fig. 6
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costly and oen not precise post-processing steps are required.
Moreover, the bulk method involves harsh mixing steps, which
may cause denaturation and reduced bioactivity of the growth
factor.36 Size polydispersity in bulk methods causes the formation of particles with various release proles as the size and
microstructure directly aﬀect the evaporation rate of the solvent
in the course of the drying step in the production process.
Hence, current methods fail to fulll the precise temporal and
spatial delivery of the VEGF to the microenvironment.37,38

RSC Advances

Photoluminescence responses and uorescence the image of
the produced MPs and are depicted in Fig. 6B. The uorescence
emission intensity of the produced MPs increased by particle
size reduction. Furthermore, slightly redshi (8 nm) in uorescence emission peak was observed for CQDs in PLGA MPs.
The successful incorporation of CQDs into the PLGA MPs can be
conrmed by the photoluminescence spectra of samples
(Fig. 5E and 6B).38
Fig. 7A shows the loading eﬃciency of PEGylated and native
VEGF loaded in PLGA MPs. According to the MPs size, the

Fig. 7 (A) The loading eﬃciency of VEGF-loaded PLGA MPs. (B) Release proﬁles of native VEGF and PEGylated VEGF released from PLGA MPs in
PBS (pH 7.4). (C) Confocal ﬂuorescence microscope images of one PLGA MPs at (a): 0, (b): 7 and (c): 14 days (scale bar ¼ 10 mm) and ﬂuorescence
intensity proﬁles of PLGA MPs and released CQDs from PLGA MPs.

This journal is © The Royal Society of Chemistry 2019
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loading eﬃciency of the produced MPs was varied from 51–69%
and 18–31% for PEGylated and native VEGF, respectively
(Fig. 7A). Frequently, the loading eﬃciency is known as a function of the particle size and for the presented MPs size range,
the loading eﬃciency of 70% is diﬃcult to achieve. Approximately 60% is the highest loading eﬃciency reported in the
literature for similar particle size.22,26,27,29 The very high loading
eﬃciency was presented by PEGylated VEGF in comparison with
native VEGF. Solubility is known as a critical parameter in the
proteins encapsulation.29 Generally, the VEGF can be loaded in
PLGA MPs by incorporation with the matrix of MPs during
fabrication or adsorption on the surface of the produced MPs.
Due to more solubility, VEGF was better incorporated by the
polymeric matrix and it was uniformly distributed in the
microspheres.22,29
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The release proles of PEGylated and native VEGF from the
PLGA microcapsules are shown in Fig. 7B. The biphasic release
proles, burst initial release (38–42% in day 1) followed by
a moderate release (29–31% released from day 1 to 28) was
observed for native VEGF. In contrast, the continuous and
approximately complete release in 28 days was seen for PEGylated VEGF (85–90% release in 28 days). The aggregated unreleasable proteins in MPs containing native VEGF was the main
reason of incomplete release of proteins. According to the low
solubility of proteins in an organic solvent, the greater amount
of native VEGF was aggregated during the homogenization
process. This issue can be solved by PEGylation of VEGF.26,27,29
Furthermore, the burst initial release of VEGF was highly
reduced for PEGylated VEGF. The control of burst initial release
is known as an important safety feature. Reduced VEGF

Fig. 8 (A) Proliferation of HUVECs cells treated with 22 and 36 mm PEGylated VEGF MPs, 22 and 36 mm native VEGF MPs, PEGylated and native
VEGF at the same concentration (25 ng mL1 for VEGF MPs and 10 ng mL1 for free VEGF) in comparison with control groups. (B) Live/death assay
of 36 mm PEGylated VEGF MPs and PEGylated VEGF treated HUVECs cells at the same concentration (25 ng mL1) in comparison with control
groups observed with ﬂuorescent microscopy (scale bar ¼ 100 mm).

33254 | RSC Adv., 2019, 9, 33246–33256
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aggregation during the mixing process, the uniform distribution of VEGF in the microspheres and larger hydrodynamic
volume are known as the main reason for the reduction in burst
initial release of PEGylated VEGF.29 The release behavior of
CQDs from PLGA MPs was studied by photoluminescence
spectroscopy and the confocal uorescence microscope image
(Fig. 7C). As shown in Fig. 7C, at same condition by increasing
uorescence emission intensity of the released CQDs in
medium, the uorescence emission intensity of the produced
MPs decreased. These results show that release proles of CQDs
are dependent on the PLGA MPs degradation. Consequently,
the released VEGF from the PLGA MPs can be traced indirectly
by CQDs.
The biological activity of VEGF-loaded MPs was conrmed by
human umbilical vein endothelial cells (HUVEC) proliferation
assay. It was shown in the literature that HUVEC cells proliferation can be promoted by VEGF.10 The eﬀect of a diﬀerent group
of VEGF-loaded MPs and VEGF on HUVECs cells viability shows
in Fig. 8. Considering the same condition, the VEGF dose for
each sample was calculated bead on load and release prole.
The cell proliferation was statistically increased in those
samples treated with PEGylated VEGF-loaded MPs and both
PEGylated and native VEGF aer 5 days when compared to the
control group. In contrast, cell proliferation in both samples
exposed to native VEGF-loaded MPs was not notably changed in
comparison with the control group. Due to chemical degradation and physical denaturation, the functionality of native
proteins like VEGF can be aﬀected when it exposed to an
organic solvent such as DMF. The results show that native VEGF
during the encapsulation process mostly lost their biological
activity. Also, these results conrm that PEGylation of VEGF not
only improve the loading and release properties of VEGF but
also keep their biological activity.

4. Conclusion
In this study, VEGF-loaded PLGA – carbon dots microspheres
were successfully produced through solid/oil/water (s–o–w),
microuidic platforms. In order to improve the protein functional and structural stability during the encapsulation process
poly(ethylene glycol) was conjugated to the VEGF. The loading
and release properties of PEGylated VEGF was signicantly
improved, and the biological properties of VEGF were fully
preserved. VEGF-loaded PLGA MPs with high encapsulation
eﬃciency, monodispersity, and appropriate release proles
were achieved by using the microuidic platforms. Furthermore, it was shown that CQDs can be indirectly used to monitor
the release of VEGF. In conclusion, the present monodisperse
and controllable VEGF loaded microspheres with reproducible
manner can be used for proteins-delivery in therapeutic and
tissue engineering applications.

Conﬂicts of interest
There are no conicts to declare.

This journal is © The Royal Society of Chemistry 2019

RSC Advances

Acknowledgements
The research reported in this paper was supported by Osteo
Science Foundation through Peter Geistlich Award. The authors
would like to thank the nancial support from this foundation.

References
1 J. Fu and D.-A. Wang, In Situ Organ-Specic Vascularization
in Tissue Engineering, Trends Biotechnol., 2018, 36(Issue 8),
834–849.
2 H. Yu, et al., Improved tissue-engineered bone regeneration
by endothelial cell mediated vascularization, Biomaterials,
2009, 30, 508–517.
3 G. Schmidmaier, R. Capanna, B. Wildemann, T. Beque and
D. Lowenberg, Bone morphogenetic proteins in critical-size
bone defects: what are the options?, Injury, 2009, 40, S39–
S43.
4 R. Dimitriou, E. Jones, D. McGonagle and P. V. Giannoudis,
Bone regeneration: current concepts and future directions,
BMC Med., 2011, 9, 66.
5 W. S. Khan, F. Rayan, B. S. Dhinsa and D. Marsh, An
osteoconductive, osteoinductive, and osteogenic tissueengineered product for trauma and orthopaedic surgery:
how far are we?, Stem Cells Int., 2011, 2012.
6 P. Hernigou, Bone transplantation and tissue engineering,
part III: allogras, bone graing and bone banking in the
twentieth century, Int. Orthop., 2015, 1–11.
7 L. A. Aponte-Tinao, M. A. Ayerza, D. L. Muscolo and
G. L. Farfalli, What Are the Risk Factors and Management
Options for Infection Aer Reconstruction With Massive
Bone Allogras?, Clin. Orthop. Relat. Res., 2015, 1–5.
8 B. Vormoor, et al., Development of a preclinical orthotopic
xenogra model of ewing sarcoma and other human
malignant bone disease using advanced in vivo imaging,
PLoS One, 2014, 9, e85128.
9 A. G. Ardakani, U. Cheema, R. A. Brown and R. J. Shipley,
Quantifying the correlation between spatially dened
oxygen gradients and cell fate in an engineered threedimensional culture model, J. R. Soc., Interface, 2014, 11,
20140501.
10 U. Lenze, et al., Inuence of osteogenic stimulation and
VEGF treatment on in vivo bone formation in hMSCseeded cancellous bone scaﬀolds, BMC Musculoskeletal
Disord., 2014, 15, 350.
11 E. Volkmer, et al., Hypoxia in static and dynamic 3D culture
systems for tissue engineering of bone, Tissue Eng., Part A,
2008, 14, 1331–1340.
12 R. J. Tomanek, K. Lotun, E. B. Clark, P. R. Suvarna and N. Hu,
VEGF and bFGF stimulate myocardial vascularization in
embryonic chick, Am. J. Physiol.: Heart Circ. Physiol., 1998,
274, H1620–H1626.
13 M. Omidi, G. Amoabediny, F. Yazdian and M. Habibi-Rezaei,
Protein-based nanobiosensor for direct detection of
hydrogen sulde, EPL, 2015, 109, 18005.
RSC Adv., 2019, 9, 33246–33256 | 33255

View Article Online

Open Access Article. Published on 17 October 2019. Downloaded on 8/6/2021 2:05:11 PM.
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

RSC Advances

14 R. R. Chen and D. J. Mooney, Polymeric growth factor
delivery strategies for tissue engineering, Pharm. Res.,
2003, 20, 1103–1112.
15 J.-Y. Lee, et al., Enhanced bone formation by controlled
growth factor delivery from chitosan-based biomaterials, J.
Controlled Release, 2002, 78, 187–197.
16 C. A. Simmons, E. Alsberg, S. Hsiong, W. J. Kim and
D. J. Mooney, Dual growth factor delivery and controlled
scaﬀold degradation enhance in vivo bone formation by
transplanted bone marrow stromal cells, Bone, 2004, 35,
562–569.
17 K. Lee, E. A. Silva and D. J. Mooney, Growth factor deliverybased tissue engineering: general approaches and a review
of recent developments, J. R. Soc., Interface, 2011, 8, 153–170.
18 T. A. Holland, Y. Tabata and A. G. Mikos, Dual growth factor
delivery from degradable oligo (poly(ethylene glycol) fumarate)
hydrogel scaﬀolds for cartilage tissue engineering, J. Controlled
Release, 2005, 101, 111–125.
19 J. E. Babensee, L. V. McIntire and A. G. Mikos, Growth factor
delivery for tissue engineering, Pharm. Res., 2000, 17, 497–
504.
20 X. Yu, A. Khalil, P. N. Dang, E. Alsberg and W. L. Murphy,
Multilayered inorganic microparticles for tunable dual
growth factor delivery, Adv. Funct. Mater., 2014, 24, 3082–
3093.
21 M. Mir, N. Ahmed and A. Rehman, Recent applications of
PLGA based nanostructures in drug delivery, Colloids Surf.,
B, 2017, 159, 217–231.
22 T. W. King and C. W. Patrick Jr, Development and in vitro
characterization of vascular endothelial growth factor (VEGF)loaded poly(D,L-lactic-co-glycolic acid)/poly(ethylene glycol)
microspheres using a solid encapsulation/single emulsion/
solvent extraction technique, J. Biomed. Mater. Res., 2000,
51(3), 383–390.
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